Abstract:INTRODUCTION: Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes implicated in the invasion and metastasis of many kinds of cancer because of their ability to degrade components of extracellular matrix. Specific tissue inhibitors of matrix metalloproteinases (TIMPs) regulate their activity. MMPs and TIMPs were identified in many neoplasm, including cancers of head and neck, lung, breast and colon cancer. In most researches a strong relation between MMPs and TIMPs expression and a clinical course of disease was observed, although there were many discrepancies between the authors. The aim of this research was to evaluate the expression of MMP1, MMP2, MMP9 and TIMP1, TIMP2, TIMP3 in head and neck cancer and to investigate the prognostic impact of these factors in patients with these tumors.MATERIAL AND METHODS: 210 patients with head and neck cancer that underwent surgical treatment with at least a 5-year follow-up were included in the study. Immunohistochemical studies were performed on formalin fixed, paraffin embedded sections by using monoclonal antibodies against MMP1, MMP2, MMP9 and TIMP1, TIMP2, TIMP3 antigens and Dako EnVision detection system.RESULTS: For all of the markers diffusion, cytoplasmatic staining of tumor cells and some surrounding stromal cells was observed. There was a correlation between TIMP2 and TIMP3 overexpression and tumors staged as III/IV (p=0,037 and p=0,022, respectively). Also, we observed a strong association between MMP2 expression and the presence of nodal metastases (p=0,013). It was found that the TIMP2 overexpression was significantly more frequent in the tumors of patients facing nodal recurrences during the follow-up period (p=0,05). Positive immunostainings of MMP1, MMP2, MMP9 and TIMP1, TIMP2 were significantly related to the higher tumor grade (G3). Specially strong correlation was seen between high TIMP2 expression and low histological differentiation (G3) (p<0,001). In univariate analysis the overall survival rate was shorter in cases with positive MMP2 and/or MMP9 expression. Patients with TIMP2 positive expression diminished both overall and disease-free survival (p=0,049). In multivariate analysis positive TIMP2 and MMP2 expressions were independent prognostic factors for overall survival. Only advanced nodal metastatic tumors (N3) were related to disease free survival.CONCLUSIONS: Our data suggest the conclusion that imbalance between matrix metalloproteinases and their inhibitors play the important role in progression of head and neck cancer and patients' prognosis.

Expression and Clinical Significance of Matrix Metalloproteinase_(-2) and Its Tissue Inhibitor of Metalloproteinase_(-2) in Thyroid Cancer

Clinical Significances of the TSHR and MMP-9 Expressions in Papillary Thyroid Carcinoma

Expression and Significance of Matrix Matalloproteinase and Tissue Inhibitor of Metalloproteinase in Human Astrocytomas

The expression of tumor metastasis suppressor gene KAI1 and matrix metalloproteinase 2 in breast cancer tissues

Prognostic Significance of MMP-2 and TIMP-2 Expression in Infiltrating Breast Cancer

Expression Profile And Clinical Significance Of Micrornas In Papillary Thyroid Carcinoma

The Expression of Matrirx Metalloproteinase and Tissue Inhibitor of Metallo-proteinase in Endometrial Child Care

Study on expression of matrix metalloproteinases and their inhibitors in parotid gland tumors

Expression and Significance of MMP-2 and TIMP-2 in Human Colorectal Carcinoma and Its Metastasis

EXPRESSION OF MATRIX METALLOPROTEINASE 2 AND TISSUE INHIBITOR OF METALLOPROTEINASE 2 Mrnas IN COLORECTAL NEOPLASIA

Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis

Identification of TIMP2 As a Prognostic Biomarker and Its Correlation with Tumor Immune Microenvironment: A Comprehensive Pan-Cancer Analysis

Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study

Expression of Tissue Inhibitor of Metalloproteinase-2 in Nasopharyngeal Carcinoma

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma

Matrix metalloproteinases and tissue inhibitors of metalloproteinases and their relationship with invasion and metastasis of nasopharyngeal carcinoma

Prognostic Value of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 in Bladder Carcinoma.

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

Correlation of Matrix Metalloproteinase-2, −9, Tissue Inhibitor-1 of Matrix Metalloproteinase and CD44 Variant 6 in Head and Neck Cancer Metastasis

Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms

Immunohistochemistry related to the diagnosis and metastasis of papillary thyroid carcinoma